Oramed Pharmaceuticals, a developer of oral delivery solutions for drugs and vaccines, announced that its wholly owned Israeli subsidiary, Oramed Ltd., was awarded a government grant amounting to a net sum of NIS 2 million (approximately $540,000), from the Office of the Chief Scientist. The funds will be used to support further R&D and clinical studies on its oral insulin capsule. Founded in 2006, Oramed’s corporate and R&D headquarters are based in Jerusalem, Israel.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments